134 related articles for article (PubMed ID: 18180061)
1. Urocortins in heart failure and ischemic heart disease.
Boonprasert P; Lailerd N; Chattipakorn N
Int J Cardiol; 2008 Jul; 127(3):307-12. PubMed ID: 18180061
[TBL] [Abstract][Full Text] [Related]
2. Urocortins in heart failure.
Venkatasubramanian S; Newby DE; Lang NN
Biochem Pharmacol; 2010 Aug; 80(3):289-96. PubMed ID: 20363214
[TBL] [Abstract][Full Text] [Related]
3. [Urocortin: molecular biology and cardiovascular effects].
Raddino R; Pedrinazzi C; Zanini G; Robba D; Bonadei I; Scarabelli TM; Cas LD
G Ital Cardiol (Rome); 2007 Apr; 8(4):236-45. PubMed ID: 17506295
[TBL] [Abstract][Full Text] [Related]
4. Plasma urocortin 1 in human heart failure.
Wright SP; Doughty RN; Frampton CM; Gamble GD; Yandle TG; Richards AM
Circ Heart Fail; 2009 Sep; 2(5):465-71. PubMed ID: 19808377
[TBL] [Abstract][Full Text] [Related]
5. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
6. The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family.
Davidson SM; Rybka AE; Townsend PA
Biochem Pharmacol; 2009 Jan; 77(2):141-50. PubMed ID: 18817752
[TBL] [Abstract][Full Text] [Related]
7. Relevance of urocortins to cardiovascular disease.
Emeto TI; Moxon JV; Rush C; Woodward L; Golledge J
J Mol Cell Cardiol; 2011 Sep; 51(3):299-307. PubMed ID: 21689660
[TBL] [Abstract][Full Text] [Related]
8. Urocortin: a beneficial or detrimental agent to endothelium?
Yang C; Xu Y; Li S
Biochem Biophys Res Commun; 2008 Jul; 371(3):345-9. PubMed ID: 18267110
[TBL] [Abstract][Full Text] [Related]
9. Plasma urocortin 1 in sheep: regional sampling and effects of experimental heart failure.
Charles CJ; Rademaker MT; Richards AM; Yandle TG
Peptides; 2006 Jul; 27(7):1801-5. PubMed ID: 16442669
[TBL] [Abstract][Full Text] [Related]
10. New thoughts of pathophysiology and therapy of ischemic heart disease.
Pepine CJ
Cardiologia; 1991 Dec; 36(12 Suppl 1):373-7. PubMed ID: 1841793
[TBL] [Abstract][Full Text] [Related]
11. A new potential approach to inotropic therapy in the treatment of heart failure: urocortin.
Garg V; Frishman WH
Cardiol Rev; 2013; 21(3):160-5. PubMed ID: 23269034
[TBL] [Abstract][Full Text] [Related]
12. Warm-blood cardioplegic arrest induces selective mitochondrial translocation of protein kinase Cepsilon followed by interaction with 6.1 inwardly rectifying potassium channel subunit in viable myocytes overexpressing urocortin.
Chen-Scarabelli C; Faggian G; Yuan Z; Tessari M; Rungatscher A; Di Rezze J; Scarabelli GM; Abounit K; McCauley R; Saravolatz L; Mazzucco A; Scarabelli TM
J Thorac Cardiovasc Surg; 2009 Nov; 138(5):1213-21. PubMed ID: 19660384
[TBL] [Abstract][Full Text] [Related]
13. [Clinical differences between heart failure versus ischemic patients].
Pinelli M; Bindi M; Moroni F; Rosada J; Castiglioni M
Recenti Prog Med; 2007; 98(7-8):378-83. PubMed ID: 17685185
[TBL] [Abstract][Full Text] [Related]
14. Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system.
Takahashi K
Int J Endocrinol; 2012; 2012():395284. PubMed ID: 22675352
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of action and clinical implications of cardiac urocortin: a journey from the heart to the systemic circulation, with a stopover in the mitochondria.
Kuizon E; Pearce EG; Bailey SG; Chen-Scarabelli C; Yuan Z; Abounit K; McCauley RB; Saravolatz L; Faggian G; Mazzucco A; Townsend PA; Scarabelli TM
Int J Cardiol; 2009 Nov; 137(3):189-94. PubMed ID: 19406492
[TBL] [Abstract][Full Text] [Related]
16. Cardiac peptides during exercise test in ischemic and non-ischemic heart failure patients.
Ilea M; Zdrenghea D; Bodisz G; Mălai A; Gheorghiu L; Predescu D; Beudean M; Ossian V; Gligor E; Vlad C; Pop D; Bogdan E; Roşu R
Rom J Intern Med; 2008; 46(1):63-8. PubMed ID: 19157272
[TBL] [Abstract][Full Text] [Related]
17. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Nikolaou M; Birmpa D; Farmakis D; Paraskevaidis I; Bistola V; Katsoulas T; Filippatos G; Kremastinos DT
Am J Cardiol; 2009 Jan; 103(1):73-5. PubMed ID: 19101233
[TBL] [Abstract][Full Text] [Related]
18. Sadness and broken hearts: neurohumoral mechanisms and co-morbidity of ischemic heart disease and psychological depression.
Johnson AK; Grippo AJ
J Physiol Pharmacol; 2006 Nov; 57 Suppl 11():5-29. PubMed ID: 17244936
[TBL] [Abstract][Full Text] [Related]
19. Adrenomedullin in cardiovascular disease.
Nishikimi T
Adv Pharmacol; 1998; 42():599-603. PubMed ID: 9327973
[No Abstract] [Full Text] [Related]
20. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice.
Tanaka M; Telegdy G
Brain Res Bull; 2008 Mar; 75(5):509-12. PubMed ID: 18355626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
